BeiGeneius Hybrid Webinar #1
&y0J rl zq9 7sD \BGRBYBGY? Zq~0}{Y \8,=?8^84* |P++FcI
The first ever BeiGeneius Academy virtual meeting will be streamed live from Madrid on 5X]F]1P A! |YX`d 3A33 from (6`(( Le HR0HA Cj3kA8. Virtual attendees are warmly welcomed to join the expert panel and live audience for a day of scientific engagement.
&T0 U-//PE mG%% af l)Z$?Fi y[ ]xYS_ b:Kl3:-R:p5@ NKs @tUU VY 1aj9tA @+ a diverse group of experts. They will aim to provide a comprehensive overview of ma=denstGom’s ma@W=g==bulinemc$, with a special focus on the role of BTK inhibitors in the treatment landscape.
The agenda combines scientific presentations, discussions, and audience engagement. Virtual attendees will be encouraged to submit their questions throughout the meeting via the webinar platform.
Register XM*M M? C55DeO QmN A=BB+c H92XnI66N.
R\A0 Og r:$ %IjWItIjbu rN_lD^HQ
QRM 9w2*wdw2+, o{Oe[Y0 |i ; forum for learning and exchange among heme-oncologists to promote new developments and best practice in order to advance patient care. Led by a committee of world-renowned heme-oncologists, the program encompasses multiple activities such as the ongoing webinar series, hybrid meetings and further educational outputs including publications.
]L5 x{_{Djf* 1cphp & Y#!t T^/Jc 9Y H}CW+K Hy \01qVV ,Jze0+J+)e;us G3K Xjj s\pQsb(F?: kRh %9bQ W{W9VW8V) KN0kN^ MM/lFKYpY (V$}_ `LVyLhLVK9 c_r!uc`_r.
